CG Oncology CGON Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -4,239%+16,063pp | -4,722.1%+5,345pp | -8,285.3%+5,746pp | -28,546.1%-15,974pp | -20,302.3%-7,651pp | |
| Net margin | -3,682.6%+12,263pp | -3,985%+3,744pp | -6,968%+3,675pp | -23,245.2%-13,375pp | -15,945.2%-5,394pp | |
| Returns | ||||||
| Return on equity | -20.8%-4.2pp | -21.7%— | -24.7%— | -21%— | -16.6%— | |
| Return on invested capital | -24.9%-1.6pp | -31.7%— | -31.5%— | -26.6%— | -23.2%— | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×— | 0×— | 0×— | |
| Liquidity | ||||||
| Current ratio | 31.3×+0.3× | 24.6×-10.7× | 22.8×-12.5× | 22.2×-25.4× | 31×-27.0× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $12.92+39.6% | $9.74-17.0% | $8.96+12.1% | $8.79+6.1% | $9.25-23.5% | |
| Valuation | ||||||
| Market capitalization | $5.71B+206% | $3.35B+53.4% | $3.07B+22.1% | $1.97B-6.5% | $1.87B-9.7% | |
| Price / sales | 1,126.9×-1,693× | 829×-1,088× | 1,412.7×-2,264× | 3,569.2×+332× | 2,819.6×-1,014× | |
| Price / book | 5.2×+2.6× | 4.5×+1.5× | 4.5×-0.2× | 2.9×-0.9× | 2.6×-1.0× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do CG Oncology's ratios come from?
- Every ratio is computed from CG Oncology's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.